Full-Time

Associate District Account Representative

Confirmed live in the last 24 hours

Dexcom

Dexcom

5,001-10,000 employees

Develops continuous glucose monitoring systems

Data & Analytics
Healthcare

Compensation Overview

$22.21 - $37.01Hourly

Entry, Junior

Company Does Not Provide H1B Sponsorship

Remote in USA

Candidates must live within the District’s territory defined in the job title.

Category
Inside Sales
Sales & Account Management
Required Skills
Sales

You match the following Dexcom's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bilingual Spanish is required
  • Must live within the District’s territory defined in the job title
  • Typically requires a Bachelor's degree and 0-2 years previous experience
  • Experience using a CRM tool in the medical device or pharmaceutical industry preferred
Responsibilities
  • Support company initiatives within the district/territory virtually as well as in person
  • Provide education and training on Dexcom products to relevant HCPs in innovative ways
  • Achieve quarterly sales goals and meet Key Performance Indicator Metrics as designated by management
  • Increase the Dexcom market share and hit district/territory targets in line with company expectations
  • Utilize company CRM to identify business development opportunities, track activities, and configure digital face-to-face presentations
  • Conduct high volume outbound cold and warm calls daily to meet product awareness goals
  • Connect and engage with prescribers and HCPs in individual and group set-ups to help customers discover, clarify, and verbalize their needs
Desired Qualifications
  • Experience using a CRM tool in the medical device or pharmaceutical industry preferred

Dexcom develops and sells continuous glucose monitoring (CGM) systems designed to help individuals manage diabetes. The main product, the Dexcom G6 CGM System, provides users with real-time glucose readings, enabling better management of their condition. The system includes a sensor that is placed under the skin to measure glucose levels continuously, and the data is sent to a smartphone or receiver for easy access. Dexcom differentiates itself from competitors by offering a user-friendly interface and advanced data analytics through its Dexcom CLARITY software, which helps users and healthcare providers make informed decisions based on glucose trends. The goal of Dexcom is to enhance the quality of life for diabetes patients by providing accurate and convenient glucose monitoring solutions.

Company Size

5,001-10,000

Company Stage

IPO

Total Funding

$51.3M

Headquarters

San Diego, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • The wearable tech market is expanding, boosting demand for Dexcom's innovative products.
  • FDA's streamlined approval process may accelerate Dexcom's time-to-market for new devices.
  • The global diabetes management market is projected to reach $98.4 billion by 2028, benefiting Dexcom.

What critics are saying

  • Increased competition from new health tech wearables could impact Dexcom's market share.
  • Potential data privacy concerns arise from integrating glucose data with other health metrics.
  • Reliance on third-party technology for GenAI platform poses data security and dependency risks.

What makes Dexcom unique

  • Dexcom's GenAI platform offers personalized insights for glucose management, enhancing user experience.
  • The Stelo sensor provides over-the-counter glucose monitoring for non-insulin Type 2 diabetes patients.
  • Dexcom's partnership with Ōura integrates comprehensive health metrics for holistic metabolic health tracking.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

0%
ETF Daily News
Jan 17th, 2025
Capital Investment Advisors LLC Invests $206,000 in DexCom, Inc. (NASDAQ:DXCM)

Capital Investment Advisors LLC invests $206,000 in DexCom, Inc. (NASDAQ:DXCM).

MedTech Dive
Jan 15th, 2025
Dexcom CEO talks Stelo sensor launch, OTC strategy

Dexcom launched its Stelo sensors last summer to offer an over-the-counter glucose monitor for people with Type 2 diabetes who don't take insulin.

South China Morning Post
Jan 12th, 2025
New health tech wearables at CES measure blood sugar, capture heart murmurs

MindMics' earbuds and DexCom's Stelo patches stand out at CES 2025, while an expert calls the approval process for such devices 'pathetic'

Dexcom
Jan 7th, 2025
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO-(BUSINESS WIRE)- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.

Elistix
Dec 17th, 2024
Dexcom launches generative AI platform for Stelo customers

Dexcom launches generative AI platform for stelo customers.